Recent Updates
Companies and Targets in Oncology

SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Complete records describing in detail the novel agents mentioned in the news summaries below may be accessed by subscribers to nm|OK by logging in. For examples of such records click here.

Company

Human Longevity
(May-11-2017)

ProLung
(May-11-2017)

Castle Biosciences
(May-9-2017)

Immune Pharmaceuticals
(May-04-2017)

Celyad
(May-3-2017)

Biotheranostics
(May-2-2017)

Wuxi NextCODE
(May-1-2017)

Agios Pharmaceuticals
(Apr-28-2017)

EnGene
(Apr-26-2017)



(Additional Company Updates available in the Archives)

Targets in Oncology

Semaphorin 3A (SEMA3A)
(May 14, 2017)

Splicing factor 3b, subunit 1 (SF3B1)
(May-14-2017)



(Additional Targets in Oncology Updates available in the Archives)

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM